These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

500 related items for PubMed ID: 33665980

  • 1. Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models.
    Chung WP, Huang WL, Liao WA, Huang WL, Liu YY, Su WC.
    Cancer Med; 2021 Apr; 10(7):2370-2379. PubMed ID: 33665980
    [Abstract] [Full Text] [Related]

  • 2. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S, Eustace AJ, Fay J, Sheehan KM, Carr A, Milewska M, Madden SF, Teiserskiene A, Kay EW, O'Donovan N, Gallagher W, Grogan L, Breathnach O, Walshe J, Kelly C, Moulton B, Kennedy MJ, Gullo G, Hill AD, Power C, Duke D, Hambly N, Crown J, Hennessy BT.
    Breast Cancer Res; 2017 Jul 27; 19(1):87. PubMed ID: 28750640
    [Abstract] [Full Text] [Related]

  • 3. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
    Du C, Yi X, Liu W, Han T, Liu Z, Ding Z, Zheng Z, Piao Y, Yuan J, Han Y, Xie M, Xie X.
    BMC Cancer; 2014 Nov 24; 14():869. PubMed ID: 25417825
    [Abstract] [Full Text] [Related]

  • 4. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
    Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D.
    Am J Pathol; 2010 Oct 24; 177(4):1647-56. PubMed ID: 20813970
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.
    Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, Schiff R, Arteaga C, Osborne CK, Chang JC.
    J Clin Oncol; 2011 Jan 10; 29(2):166-73. PubMed ID: 21135276
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
    Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C, Schiff R.
    Breast Cancer Res Treat; 2018 Feb 10; 167(3):731-740. PubMed ID: 29110152
    [Abstract] [Full Text] [Related]

  • 11. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
    Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H.
    Ann Oncol; 2010 Feb 10; 21(2):255-262. PubMed ID: 19633047
    [Abstract] [Full Text] [Related]

  • 12. Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer.
    Lee JY, Joo HS, Choi HJ, Jin S, Kim HY, Jeong GY, An HW, Park MK, Lee SE, Kim WS, Son T, Min KW, Oh YH, Kong G.
    J Natl Cancer Inst; 2019 Jun 01; 111(6):609-619. PubMed ID: 30265336
    [Abstract] [Full Text] [Related]

  • 13. Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.
    Garay JP, Smith R, Devlin K, Hollern DP, Liby T, Liu M, Boddapati S, Watson SS, Esch A, Zheng T, Thompson W, Babcock D, Kwon S, Chin K, Heiser L, Gray JW, Korkola JE.
    Breast Cancer Res; 2021 Aug 03; 23(1):81. PubMed ID: 34344439
    [Abstract] [Full Text] [Related]

  • 14. The predictive role of phosphatase and tensin homolog (PTEN) loss, phosphoinositol-3 (PI3) kinase (PIK3CA) mutation, and PI3K pathway activation in sensitivity to trastuzumab in HER2-positive breast cancer: a meta-analysis.
    Wang Y, Liu Y, Du Y, Yin W, Lu J.
    Curr Med Res Opin; 2013 Jun 03; 29(6):633-42. PubMed ID: 23574264
    [Abstract] [Full Text] [Related]

  • 15. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
    Perez EA, de Haas SL, Eiermann W, Barrios CH, Toi M, Im YH, Conte PF, Martin M, Pienkowski T, Pivot XB, Burris HA, Stanzel S, Patre M, Ellis PA.
    BMC Cancer; 2019 May 30; 19(1):517. PubMed ID: 31146717
    [Abstract] [Full Text] [Related]

  • 16. Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer.
    Loibl S, Darb-Esfahani S, Huober J, Klimowicz A, Furlanetto J, Lederer B, Hartmann A, Eidtmann H, Pfitzner B, Fasching PA, Tiemann K, Jackisch C, Mehta K, von Minckwitz G, Untch M, Denkert C.
    Clin Cancer Res; 2016 Jun 01; 22(11):2675-83. PubMed ID: 26758558
    [Abstract] [Full Text] [Related]

  • 17. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.
    Breast Cancer Res Treat; 2011 Nov 01; 130(1):29-40. PubMed ID: 21153051
    [Abstract] [Full Text] [Related]

  • 18. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.
    Gardaneh M, Shojaei S, Kaviani A, Behnam B.
    Breast Cancer Res Treat; 2017 Apr 01; 162(2):231-241. PubMed ID: 28116540
    [Abstract] [Full Text] [Related]

  • 19. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells.
    Rexer BN, Chanthaphaychith S, Dahlman K, Arteaga CL.
    Breast Cancer Res; 2014 Jan 23; 16(1):R9. PubMed ID: 24451154
    [Abstract] [Full Text] [Related]

  • 20. A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
    Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick AC, Contreras A, Nuciforo P, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Wolff AC, Krop IE, Fuqua SAW, Prat A, Hilsenbeck SG, Weigelt B, Reis-Filho JS, Gutierrez C, Osborne CK, Rimawi MF, Schiff R.
    Ann Oncol; 2019 Jun 01; 30(6):927-933. PubMed ID: 30903140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.